// App-Quantinova.ai

: Initial Efficacy and Safety of Acalabrutinib Plus RICE in Transplant Eligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Researchers

Presenter

  • Neil Bailey

Principal Investigators

  • Megumi Bailey

  • Tenzin Tsomo

  • Jennie Szeto

  • Sandra Benitez Kruidenier

  • Vanessa Dunleavy

  • Joanna Fesler

  • Gayle Funk

  • Sonia Glennie

  • Judson Hall

  • Julia Parker

  • Daniel Egan

  • Raya Mawad

  • Carol A Dean

  • Suzan Sullivan

  • Chia Lu

  • Heidi Hohmann

  • Jordan Briggs

  • Krish Patel

Medical Centers

  • Swedish Center for Blood Disorders and Cellular Therapy, Seattle, WA

  • Swedish Cancer Institute, Center for Blood Disorders and Cellular Therapy, Seattle

  • Center for Blood Disorders and Stem Cellular Therapy, Swedish Cancer Institute, Seattle, WA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

  • Lymphomas

Biomarkers

  • Hematocrit

  • Circulating DNA

Drug/Treatment

  • ACP-196

  • Recil

Outcome

  • N/A

Study Design

  • Efficacy

  • Safety

  • Open Label

  • Tolerability

  • Cohort

  • Single Center

  • Feasibility

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved